INO 8000

Drug Profile

INO 8000

Alternative Names: Hepatitis C vaccine - Inovio/VGX; INO-8000; VGX-6150

Latest Information Update: 23 Aug 2016

Price : $50

At a glance

  • Originator University of Pennsylvania
  • Developer GeneOne Life Science; Inovio Pharmaceuticals; Mayo Clinic
  • Class DNA vaccines; Hepatitis C vaccines
  • Mechanism of Action Hepatitis C virus NS 5 protein inhibitors; Hepatitis C virus NS3 protein inhibitors; Hepatitis C virus NS4 protein inhibitors; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Hepatitis C

Most Recent Events

  • 01 Jul 2016 Inovio Pharmaceuticals and National Cancer Institute initiate enrolment in a phase I trial for Hepatitis C in USA (NCT02772003)
  • 01 Jun 2016 Phase-I clinical trials in Hepatitis C in USA (IM) (NCT02822079)
  • 12 May 2016 Inovio Pharmaceuticals and National Cancer Institute plan a phase I trial for Hepatitis C in USA (IM) (NCT02772003)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top